2-(Arylalkoxy)-1-phenylethylamine derivatives as nk1 antagonist and serotonin reuptake inhibitors

A compound according to structural diagram I:

• wherein:
• R1 and R2 are independently selected from C1-6alkyl or C16alkenyl, or together with the N to which they are bound, form a heterocycle containing 6, 7 or 8 atoms or such a heterocycle substituted with moieties independently selected from hydrogen, halogen, C1-4alkyl, C1-4alkoxy or C1-4alkyl substituted with 1, 2 or 3 halo moieties, amino, or amino substituted with C1-4alkyl, C1-4alkoxy or C1-4alkyl, substituted with 0, 1, 2, or 3 halo moieties;
• R4 is hydrogen;
• n is 0, 1 or 2;
• Ar1 is phenyl or phenyl substituted with moieties independently selected from hydrogen, halogen, —S—C1-4alkyl, C1-4alkyl, C1-4alkoxy or C1-4alkyl substituted with 1, 2 or 3 halo moieties;
• and
• Ar2 phenyl, naphthyl, tetralin, or phenyl, naphthyl or tetralin substituted with moieties independently selected from hydrogen, halogen, cyano, nitro, C1-4alkyl, C1-4alkoxy or C1-4alkyl substituted with 1, 2 or 3 halo moieties;
• in vivo hydrolysable precursors and pharmaceutically-acceptable salts thereof.